News & Events

Upcoming Events

Tue, 2/7/2023 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
Tue, 2/14/2023 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
Wed, 2/15/2023 - 12:00 PM ET
Join us the 3rd Wednesday of every month to connect with others who… more
Thu, 2/16/2023 - 6:30 PM ET
For patients/survivors General meetup for those impacted by lung… more
Tue, 2/21/2023 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more

Trial to Investigate Novel Drug in KRAS-Mutant Lung Cancer

Trial to Investigate Novel Drug in KRAS-Mutant Lung Cancer

Guideline for oncogene-addicted metastatic NSCLC issued by ESMO

Guideline for oncogene-addicted metastatic NSCLC issued by ESMO

Real-World Data Confirm Safety, Efficacy of Durvalumab After CRT in NSCLC

Real-World Data Confirm Safety, Efficacy of Durvalumab After CRT in NSCLC

How Two Sisters Rallied Together to Navigate a Devastating Lung Cancer Diagnosis

How Two Sisters Rallied Together to Navigate a Devastating Lung Cancer Diagnosis

FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC

FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC

FDA Approves ctDx FIRST Companion Diagnostic for KRAS G12C-Mutated NSCLC

FDA Approves ctDx FIRST Companion Diagnostic for KRAS G12C-Mutated NSCLC

Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC

Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC

FDA Approves Second KRAS Drug for Lung Cancer

FDA Approves Second KRAS Drug for Lung Cancer

FDA approves adagrasib for certain adults with non-small cell lung cancer

FDA approves adagrasib for certain adults with non-small cell lung cancer

Dr. Spira on the FDA Approval of Adagrasib in KRAS G12C–mutant NSCLC

Dr. Spira on the FDA Approval of Adagrasib in KRAS G12C–mutant NSCLC